A natural mutation between SARS-CoV-2 and SARS-CoV determines neutralization by a cross-reactive antibody

Mostrar otras versiones (1)

Epitopes that are conserved among SARS-like coronaviruses are attractive targets for design of cross-reactive vaccines and therapeutics. CR3022 is a SARS-CoV neutralizing antibody to a highly conserved epitope on the receptor binding domain (RBD) on the spike protein that can cross-react with SARS-C...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Nicholas C., Yuan, Meng, Bangaru, Sandhya, Huang, Deli, Zhu, Xueyong, Lee, Chang-Chun D., Turner, Hannah L., Peng, Linghang, Yang, Linlin, Nemazee, David, Ward, Andrew B., Wilson, Ian A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523114/
https://www.ncbi.nlm.nih.gov/pubmed/32995788
http://dx.doi.org/10.1101/2020.09.21.305441

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523114/
https://www.ncbi.nlm.nih.gov/pubmed/32995788
http://dx.doi.org/10.1101/2020.09.21.305441

Ejemplares similares